Want to see SE:ACE full AI Analyst Report?
Ascelia Pharma AB (ACE) AI Stock Analysis
Ascelia Pharma AB
(Nasdaq OMX AB:ACE)
The overall score is heavily pressured by the company's pre-revenue status and significant cash burn, which present a high-risk profile. The clean balance sheet with minimal debt provides some stability, but the shrinking asset base is a major concern. Technicals show a neutral short-term picture within a long-term downtrend, and the negative P/E ratio confirms the lack of current profitability. The primary risk is the finite cash runway, which is the most critical factor for investors to monitor.
Ascelia Pharma AB (ACE) vs. iShares MSCI Sweden ETF (EWD)
- Market Cap
- SEK 77.45M
- Dividend Yield
- ―
- Average Volume (3M)
- 1.03M
- Price to Earnings (P/E)
- -1.2
- Beta (1Y)
- 0.62
- Revenue Growth
- ―
- EPS Growth
- 58.15%
- Country
- Sweden
- Employees
- 10
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Ascelia Pharma AB Business Overview & Revenue Model
Company Description
Ascelia Pharma AB (publ) is a Swedish biotechnology company concentrating on the development of orphan drugs for cancer treatment. The firm is currently progressing Mangoral, an innovative non-gadolinium contrast agent, through Phase 3 clinical trial...
How the Company Makes Money
Ascelia Pharma’s business model is centered on successfully developing, obtaining regulatory approval for, and then commercializing its product candidates, with future revenues expected to come primarily from product sales of its lead candidate, Orvi...
Ascelia Pharma AB Financial Statement Overview
Summary
The company is pre-revenue with deeply negative margins, resulting in a minimal Income Statement score. The balance sheet is clean with negligible debt, but assets are shrinking rapidly due to cash burn. Cash flow is a critical concern with a high and consistent burn rate, though it has improved from 2023 peaks. Overall, the financial profile is high-risk, typical of clinical-stage biotech, with survival dependent on the current cash runway.
Income Statement
1Very NegativeBalance Sheet
65PositiveCash Flow
10Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | -888.00K | -938.00K | -1.05M | -3.89M | -8.72M |
| EBITDA | -59.92M | -73.24M | -66.83M | -108.56M | -132.06M | -128.42M |
| Net Income | -60.13M | -76.25M | -80.03M | -109.29M | -131.22M | -125.90M |
Balance Sheet | ||||||
| Total Assets | 100.23M | 111.94M | 140.92M | 87.07M | 218.57M | 333.49M |
| Cash, Cash Equivalents and Short-Term Investments | 38.05M | 49.86M | 75.26M | 21.86M | 149.56M | 261.60M |
| Total Debt | 490.00K | 1.04M | 25.40M | 1.06M | 484.00K | 1.66M |
| Total Liabilities | 10.40M | 12.47M | 61.98M | 12.74M | 37.71M | 25.66M |
| Stockholders Equity | 89.83M | 99.47M | 78.94M | 74.33M | 180.86M | 307.83M |
Cash Flow | ||||||
| Free Cash Flow | -67.19M | -72.31M | -62.84M | -126.79M | -125.33M | -116.60M |
| Operating Cash Flow | -67.19M | -72.25M | -62.84M | -126.79M | -125.26M | -116.56M |
| Investing Cash Flow | 0 | -57.00K | 0 | 46.00K | -65.00K | -38.00K |
| Financing Cash Flow | 45.00M | 48.21M | 115.19M | -936.00K | -1,100 | 184.87M |
Ascelia Pharma AB Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:ACE, the sentiment is Neutral. The current price of 0.58 is below the 20-day moving average (MA) of 0.62, below the 50-day MA of 0.63, and below the 200-day MA of 1.96, indicating a bearish trend. The MACD of -0.04 indicates Positive momentum. The RSI at 46.86 is Neutral, neither overbought nor oversold. The STOCH value of 52.30 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for SE:ACE.
Ascelia Pharma AB Peers Comparison
Overall Rating
SE:CANTA70Outperform
SE:ONCO47Neutral
SE:BINV43Neutral
SE:IMMU43Neutral- SE:ACE42Neutral
SE:ONCOZ38Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| SE:CANTA | 70Outperform | SEK 451.68M | 2.35 | 63.09% | ― | ― | ― |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| SE:ONCO | 47Neutral | SEK 721.66M | -2.14 | ― | ― | 87.23% | 35.27% |
| SE:BINV | 43Neutral | SEK 357.32M | -0.73 | -128.54% | ― | -83.67% | -50.29% |
| SE:IMMU | 43Neutral | SEK 348.89M | -3.07 | -18.05% | ― | ― | 15.97% |
| SE:ACE | 42Neutral | SEK 77.45M | -1.20 | -62.21% | ― | ― | 58.15% |
| SE:ONCOZ | 38Underperform | SEK 85.84M | -1.62 | -2775.09% | ― | 115.26% | -230.43% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| SE:ACE | Ascelia Pharma AB | 0.58 | -2.63 | -81.93% | |
| SE:BINV | BioInvent International AB | 5.43 | -28.47 | -83.98% | |
| SE:ONCO | Oncopeptides AB | 1.67 | -3.75 | -69.16% | |
| SE:ONCOZ | OncoZenge AB | 3.11 | -1.14 | -26.75% | |
| SE:IMMU | Immunicum AB | 5.50 | -1.89 | -25.58% | |
| SE:CANTA | Cantargia AB | 1.60 | -1.97 | -55.13% |
Ascelia Pharma AB Corporate Events
Ascelia Pharma Charts New Path for Orviglance After FDA Meeting
Ascelia Pharma has received official minutes from its Type A meeting with the U.S. FDA regarding the Complete Response Letter for the Orviglance New Drug Application, confirming that the agency still wants additional clinical evidence, ideally from a...
Ascelia Pharma’s Orviglance Study Published in Leading MRI Journal
Ascelia Pharma AB, a Malmö-based biotech company listed on Nasdaq Stockholm and focused on orphan oncology treatments, is developing two key drug candidates: Orviglance, a manganese-based MRI contrast agent for liver imaging, and Oncoral. The co...
Ascelia Pharma Holds FDA Type A Meeting on Orviglance NDA
Ascelia Pharma has completed a Type A meeting with the U.S. Food and Drug Administration to discuss the Complete Response Letter issued for the Orviglance New Drug Application. The meeting was aimed at clarifying the steps required to secure U.S. reg...
Ascelia Pharma Tightens Costs After FDA Setback on Orviglance
Ascelia Pharma reported that its primary focus in the first half of 2026 has been advancing Orviglance through the U.S. regulatory process and preparing for potential commercial partnering once approval is secured. The company completed a SEK 20 mill...
Ascelia Pharma Secures FDA Type A Meeting on Orviglance NDA
Ascelia Pharma said the U.S. Food and Drug Administration has scheduled a Type A meeting on September 9, 2026 to discuss the Complete Response Letter issued for the New Drug Application of Orviglance. The meeting will allow the company and the regula...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 13, 2026